ALX ONCOLOGY HOLDINGS INC
ALX Oncology is a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives. They focus on innovative approaches to optimize future standards of care. Their lead therapeutic candidate, evorpacept, has demonstrated potential as a cornerstone in immuno-oncology.
Offisielt Register
Sist verifisert: 1/2/2026
AI Kvalitetsanalyse
Tillitsscore Detaljer
Snarveier
Nettside Høydepunkter
🌟 Lignende Pålitelige Bedrifter
Context Therapeutics Inc.
Context Therapeutics is dedicated to advancing the treatment of solid tumors through the development of next-generation T cell engaging (TCE) bispecific antibody therapies. Their innovative pipeline features clinical-stage bispecific therapeutics designed to harness the immune system for targeted cancer eradication. The company focuses on innovative immunotherapeutic solutions, transforming cancer care and improving outcomes for patients.
AGENUS INC
Agenus is a biotechnology company focused on developing and commercializing immuno-oncology therapies. Their key products include botensilimab and balstilimab, which are in clinical trials for various cancers. The company is positioned as an innovator in the development of next-generation immunotherapies.
Evaxion A/S
Evaxion utilizes its AI-Immunology™ platform to challenge and improve standardized treatments. In oncology, they create personalized therapies, tailoring treatment to the individual. For infectious diseases, they design next-generation vaccines to address unmet medical needs. Their AI platform accelerates vaccine target discovery, design, and development.